No match scores

Peptide finder

Pick what you want to change. See every compound measured for it in people, most people first. Each one shows what the study found, and the failures are counted.

Plate 11

Goal map

Find by outcome

Goal pages

Record

Pick your goal. What was measured opens up, including the gaps.

The short answer

Pick what you want to change. See every compound measured for it in people, most people first. Each one shows what the study found, and the failures are counted. 70 of 453 compounds here have no study in people of any kind.

Compounds: 453
No study in people: 70

How this ranks

No match scores

Other tools print a match percentage. Nobody measured those numbers. This page shows how many people each goal was measured in, and names the goals nobody has measured in a person.

A thin record in people is usually about who pays for trials. It is not a verdict on the compound.

What users report sits next to the trial count. It is never added into it.

What are you trying to change?

Pick as many as you like. The number on each one is how many people it has been measured in across the whole archive. So you can see where the evidence is before you choose.

Body composition

Metabolic

Repair and pain

Brain

Looks

Hormones

Heart and circulation

Long game

Somebody handed you a stack. What is actually known about it?

Add what you are looking at. You get every goal those compounds have been measured for in people. Then you get the longer list of goals they have not.

Sleep

Does it improve sleep?

Sleep gets claimed constantly and measured rarely. Where a trial used polysomnography rather than a questionnaire, that is worth a great deal more.

187 people · 8 studies in people · 6 compounds

01OveporextonSmall moleculeModerate. At least one finished study in people, and at least 100 people who took it. 6 completed trials, 441 people given it.
168 people2 studies
- This is about as strong as evidence for a sleep drug gets. Two trials put people with narcolepsy type 1 on oveporexton pills or dummy pills for three months. Nobody involved knew which. People on the drug stayed awake far longer on a standard staying-awake test, while the dummy group drifted slightly the other way....
  New England Journal of Medicine, 2026 · 168 people
- The earlier and smaller test pointed the same way. 112 people with narcolepsy type 1 were split by chance across four dose schedules or a dummy, for two months. People on the drug stayed awake much longer on the standard test, while the dummy group slipped slightly. Insomnia hit about half of them, and a third had a...
  New England Journal of Medicine, 2025 · number of people not given
02SermorelinPeptideModerate. At least one finished study in people, and at least 100 people who took it. 3 completed trials, 139 people given it.8 reported
19 people1 study1 found nothing
- found nothingThe hormone response faded while the injections carried on. Nineteen adults aged 55 to 71 injected salt water nightly for a month, then a sermorelin-like peptide for four more months. Growth hormone and its main blood marker rose within two weeks, stayed up for three months, then drifted back to where they started...
  Journal of Clinical Endocrinology and Metabolism, 1997 · 19 people
03DSIPPeptideLimited. People have taken it in a published study, but fewer than 100 of them. 6 completed trials, 7 people given it.8 reported
number of people not given2 studies
- Sleep improved slightly, and the researchers said the improvement was not worth much. 16 people with long term sleeplessness were matched into pairs, and nobody knew who got DSIP and who got sugar water. Each had a vein injection before three of five nights in a sleep lab. Those on DSIP fell asleep faster and slept a...
  Neuropsychobiology, 1992 · number of people not given
- Withdrawal signs eased, and the study cannot prove the drug did it. 107 hospital patients in Geneva coming off alcohol or opioids got vein injections up to six times a day. Most of those assessed had a clear drop in visible signs: racing heart, tremor, sweating and watering eyes. Within one to three days of stopping,...
  European Neurology, 1984 · number of people not given
04TirzepatidePeptideStrong. At least two finished studies in people, and at least 1,000 people who took it. 9 completed trials, 22,802 people given it.11 reported
number of people not given1 study
- It worked for sleep apnea, and the change was big. Adults with obesity and moderate to severe sleep apnea took tirzepatide or a dummy injection for a year, across two trials. Breathing interruptions during sleep dropped by roughly 25 an hour more than on the dummy. That count is the measure doctors use to grade how...
  New England Journal of Medicine, 2024 · number of people not given
05MK-677Small moleculeLimited. People have taken it in a published study, but fewer than 100 of them. 2 completed trials, 65 people given it.11 reported
number of people not given1 study
- MK-677 deepened sleep in young adults. Young and older volunteers each took the drug and a dummy in turn, so every person acted as their own comparison. In the young group the deepest stage of sleep rose by about half, and dreaming sleep by more than a fifth. The figures reported are for the young subjects, not the...
  Neuroendocrinology, 1997 · number of people not given
06GHRP-6PeptideLimited. People have taken it in a published study, but fewer than 100 of them. 5 completed trials, 42 people given it.8 reported
number of people not given1 study1 found nothing
- found nothingThis is where the cortisol worry about GHRP-6 comes from, and it is a human measurement. Healthy men were given four small injections across one night, against a dummy on another. Growth hormone roughly tripled, and so did cortisol, with the stress hormone that drives it rising too. Light sleep gained about...
  Neuroendocrinology, 1995 · number of people not given
07EpitalonPeptideModerate. At least one finished study in people, and at least 100 people who took it. 5 completed trials, 266 people given it.6 reported
number of people not given0 studies
08NMNSupplementLimited. People have taken it in a published study, but fewer than 100 of them. 4 completed trials, 94 people given it.6 reported
number of people not given0 studies
09SomatropinBiologicLimited. People have taken it in a published study, but fewer than 100 of them. 2 completed trials, 84 people given it.9 reported
number of people not given0 studies
10HCGBiologicLimited. People have taken it in a published study, but fewer than 100 of them. 2 completed trials, 55 people given it.8 reported
number of people not given0 studies
11Vitamin B12SupplementLimited. People have taken it in a published study, but fewer than 100 of them. 2 completed trials, none stating how many people.4 reported
number of people not given0 studies
12RapamycinSmall moleculeLimited. People have taken it in a published study, but fewer than 100 of them. 2 completed trials, 25 people given it.8 reported
number of people not given0 studies
13EnclomipheneSmall moleculePreliminary. Studied in people, but no published study has had people take it. 1 human study where nobody was given it.6 reported
number of people not given0 studies
14TestosteroneHormoneModerate. At least one finished study in people, and at least 100 people who took it. 1 completed trial, 5,246 people given it.10 reported
number of people not given0 studies
15OxandroloneHormonePreliminary. Studied in people, but no published study has had people take it. 1 human study where nobody was given it.5 reported
number of people not given0 studies
16DHEAHormoneModerate. At least one finished study in people, and at least 100 people who took it. 3 completed trials, 267 people given it.5 reported
number of people not given0 studies
17BromantaneSmall moleculeModerate. At least one finished study in people, and at least 100 people who took it. 3 completed trials, 728 people given it.6 reported
number of people not given0 studies
18ClenbuterolSmall moleculeLimited. People have taken it in a published study, but fewer than 100 of them. 2 completed trials, 11 people given it.5 reported
number of people not given0 studies
19PQQSupplementModerate. At least one finished study in people, and at least 100 people who took it. 3 completed trials, 116 people given it.5 reported
number of people not given0 studies
20Modified GRF 1-29PeptideLimited. People have taken it in a published study, but fewer than 100 of them. 1 completed trial, none stating how many people.9 reported
number of people not given0 studies
21Vitamin DSupplementStrong. At least two finished studies in people, and at least 1,000 people who took it. 2 completed trials, 25,871 people given it.4 reported
number of people not given0 studies
22MagnesiumSupplementLimited. People have taken it in a published study, but fewer than 100 of them. 1 completed trial, 46 people given it.4 reported
number of people not given0 studies

How this is counted

Studies in people only. Animal and lab work never goes into this ranking, because your question was about a person.

A compound is listed for a goal only when a study on its own page names that goal and reports a result for it. Just naming it is not enough. Say a paper measures testosterone but reports a result about something else. That does not count as testosterone evidence. This tool made that mistake on its first run, and it no longer does.

People counts come from the study lines themselves, and when in doubt they count low. If a line gives no number, the study still counts as a study but adds nobody to the people count. Counts are never added up across compounds, because the same person can be in more than one trial.

The order is by how many people were measured. That is a fact about the evidence, not a judgement about the compound. It is the only order this site will defend. A compound at the top of a list is the most studied. That is not the same as the best.

Nothing here is advice. Nothing here tells you to take anything.

How we grade evidence